Nabriva Therapeutics Plc 4
4 · Nabriva Therapeutics Plc · Filed Jun 28, 2017
Insider Transaction Report
Form 4
Sender Gary
Chief Financial Officer
Transactions
- Other
Stock Option
2017-06-23+88,800→ 88,800 totalExp: 2026-05-30→ Ordinary Shares (88,800 underlying) - Other
Ordinary Shares
2017-06-23+2,200→ 2,200 total - Other
Stock Option
2017-06-23+113,000→ 113,000 totalExp: 2027-02-06→ Ordinary Shares (113,000 underlying)
Footnotes (5)
- [F1]Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG. The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc.
- [F2]The exercise price is 6.50 Euro.
- [F3]This option was granted on May 31, 2016. Vesting began on May 31, 2016 and ends on May 31, 2020. Twenty-five percent (25%) of the option will vest on May 31, 2017, and the remaining seventy-five percent (75%) vests on a monthly pro-rata basis over the remaining vesting period.
- [F4]The exercise price is 7.963 Euro.
- [F5]This option was granted on February 7, 2017. Vesting began on February 28, 2017 and will end on February 28, 2021. Twenty-five percent (25%) of the option will vest on February 28, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.